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showed catch-up growth (SGA-Cu), 410 idiopathic short 
stature (ISS) and 394 controls. We related genotype to pre- 
and/or postnatal growth parameters, response to growth 
hormone (if applicable) and blood pressure.  Results: We 
found several clinical associations for  GH1, GHR, IGF1, IGF1R, 
PPARγ  and  MAPK1. One SNP remained significant after Bon-
ferroni’s correction:  IGF1R SNP rs4966035’s minor allele A 
was significantly more prevalent among SGA and associated 
with smaller birth length (p = 0.000378) and birth weight 
(weaker association), independent of gestational age.  Con-
clusion:  IGF1R SNP rs4966035 is significantly associated with 
birth length, independent of gestational age. This and other 
associations suggest that polymorphisms in these genes 
might partly explain the phenotype of short children born 
SGA and children with ISS.  © 2013 S. Karger AG, Basel 
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 Abstract 
 Background: Fetal growth failure has been associated with 
an increased risk of hypertension, cardiovascular disease 
and diabetes in adulthood. Exploring the mechanisms un-
derlying this association should improve our understanding 
of these common adult diseases.  Patients and Methods: We 
investigated 225 SNPs in 10 genes involved in growth and 
glucose metabolism ( GH1, GHR, IGF1, IGF1R, STAT5A, STAT5B, 
MAPK1, MAPK3, PPARγ  and INS ) in 1,437 children from the 
multinational NESTEGG consortium: 345 patients born small 
for gestational age who remained short (SGA-S), 288 who 
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 Introduction 
 Growth in early life is a complex process that is influ-
enced by genetic, endocrine, nutritional and many other 
factors. Although the major endocrine determinants of 
growth have been intensively studied, our understanding 
of other aetiological mechanisms is incomplete. This is 
important for several reasons. Firstly, fetal growth failure 
is associated with long-term consequences to adult car-
diometabolic health. Specifically, small size at birth has 
been associated with an increased risk of diabetes, hyper-
tension and cardiovascular disease in adulthood  [1–4] . 
Secondly, up to now therapeutic options in fetal growth 
failure are very limited and tend not to focus on reversal 
of the underlying defect. Thirdly, although improvement 
in linear postnatal growth of the child can often be 
achieved with growth hormone (GH), the underlying de-
fect is usually not GH deficiency. Therefore, increased in-
sight into the pathophysiology might be the first step to-
wards an individualized therapeutic stratification.
 Several large-scale epidemiological studies have shown 
that maternal, paternal and fetal genetic factors play a ma-
jor role in determination of birth size  [5–11] , as reviewed 
by Dunger et al.  [5] . However, progress in understanding 
precisely which genetic factors are important has been 
slow. As has been found with a number of complex dis-
orders, investigation of uncommon single gene disorders 
provides some insight into the prevailing mechanisms. 
Mutations in insulin-like growth factor 1  (IGF1) , its re-
ceptor  (IGF1R) and glucokinase have been recognised as 
having a causative role in rare cases of small for gesta-
tional age birth size  [12–19] . Demonstrating a role for 
these and other genes in populations has been more dif-
ficult and has frequently focused on a small number of 
polymorphisms in the genes studied in small- or medi-
um-sized affected cohorts in comparison to controls.
 The Network of European Studies of Genes in Growth 
(NESTEGG) study is a large European study that aims to 
characterize in detail children with pre- and/or postnatal 
growth failure and their parents in order to study the ge-
netic basis of growth failure  [20, 21] . The study includes 
children born small for gestational age (SGA) who re-
mained short later in life (SGA-S) and those who showed 
spontaneous catch-up growth (SGA-Cu). SGA is defined 
as birth weight and/or length at least 2 standard devia-
tions (SD) below the mean for gestational age (<–2 SD) 
 [22] . Furthermore, the study includes children with idio-
pathic short stature (ISS). ISS is defined auxologically by 
a height below –2 SD score (SDS) after exclusion of any 
known specific cause for short stature  [23] . The  NESTEGG 
study was established in 2001 in four major centres (Rot-
terdam, Toulouse, Tuebingen and London) and concen-
trated on rigorous phenotyping of affected trios, unaf-
fected siblings when available, and normal controls. For 
all patients, birth weight, birth length, birth head circum-
ference, systolic (SBP) and diastolic (DBP) blood pres-
sure, and height and weight before start of GH treatment 
were available, as well as their response to GH treatment. 
 Although both genotyping and analytical techniques 
have evolved substantially since the inception of this 
study, the resulting database and DNA collection pro-
vides a unique resource with which to investigate the ge-
netic basis of growth failure. Furthermore, our study pop-
ulation of 1,437 patients might seem small in an era in 
which large genome-wide association studies (GWAS) 
dominate the literature. However, since the incidence of 
SGA births is low (by definition 2.5% of all births,  [22] ) 
our SGA population represents a population of about 
25,000 individuals.
 In the current study, we investigated 225 SNPs in 10 
genes involved in pre- and/or postnatal growth and 
 glucose metabolism ( fig.  1 ):  GH1, GHR, IGF1, IGF1R, 
 STAT5A, STAT5B, MAPK1, MAPK3, PPARγ  and INS . 
We hypothesised that minor genetic changes (polymor-
phisms) in these genes might explain part of the pheno-
type of children born SGA or children with ISS and their 
response to GH treatment.
 Patients and Methods 
 The NESTEGG project consists of the study of children born 
SGA, children with ISS and healthy controls in four different 
 European countries according to a standard protocol. Detailed 
phenotypic features were recorded and blood sampling was under-
taken to provide DNA  [21] . Of the 1,437 children studied, 544 were 
recruited in the Netherlands (Sophia’s Children’s Hospital, Eras-
mus Medical Centre Rotterdam), 455 in France (University Hos-
pital, Toulouse), 239 in Germany (University Children’s Hospital, 
Tuebingen) and 199 in the UK (St. Bartholomew’s and the Royal 
London Hospitals, London). Approval was obtained from the cor-
responding ethical committees in all countries.
 SGA children were included when birth weight and/or birth 
length was less than –2.0 SDS, according to national growth charts 
for each centre. 
 Height at or after 3 years of age determined whether a child 
had experienced spontaneous catch-up growth (height SDS >–2.0 
SDS: SGA catch-up or SGA-Cu) or remained short (height SDS 
<–2.0 SDS: short SGA or SGA-S). Subjects in the ISS group had a 
birth weight and/or birth length above –2.0 but less than +2.0 SDS 
and a height at the time of study of <–2.0 SDS without specific 
pathology.
 Exclusion criteria were severe chronic illness or endocrine dis-
ease, positive gliadin, endomysial or reticulin antibodies, GH defi-
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ciency, severe disproportionate short stature, psychosocial dwarf-
ism, chromosomal or genetic anomalies, syndromes or dysmor-
phic features (except Silver-Russell syndrome), any psychiatric, 
neurodegenerative or chronic illness in the patients or parents, 
adoption and/or lack of ability to give informed consent. 
 Genetic Techniques 
 Tagging SNPs were selected from HapMap within the region 
20 kb upstream and 10 kb downstream of  each gene, with selec-
tion criteria being R 2 higher than 0.8 and mean allele frequency 
higher than 0.05. Tag calculation methods used were Tagger and 
 LDSelect. We selected 225 SNPs: 3 SNPs for  GH1,  22 SNPs for 
 GHR , 2 for  STAT5A , 5 for  STAT5B , 8 for  MAPK1 , 3 for  MAPK3, 
38 for  PPARγ , 13 for INS, 25 for  IGF1 and 106 SNPs for  IGF1R .
 Genotypes were determined using the TaqMan allelic discrim-
ination assay. PCR was performed in 384-well PCR plates in an 
ABI 9700 PCR system (Applied Biosystems Inc., Foster City, Calif., 
USA) and consisted of initial denaturation for 10 min at 95° and 
40 cycles with denaturation of 15 s at 92° and annealing and exten-
sion for 60 s at 60°. Results were analysed by ABI TaqMan 7900HT 
using the sequence detection system 2.22 software (Applied Bio-
systems Inc.).
 Phenotypic Data 
 For all patients, birth weight, birth length, birth head circum-
ference, SBP and DBP were collected, as well as height and weight 
before the start of GH treatment and response to GH treatment (if 
applicable). Weight, height, head circumference and blood pres-
sure were converted to SDS for statistical analysis. Body mass in-
dex (BMI) was calculated as kg/m 2 . Response to GH treatment was 
defined as increase in height SDS per year of GH treatment.
 Statistical Analysis 
 We used Pearson’s χ 2 to test for deviations from Hardy-Wein-
berg equilibrium and for differences in genotype distribution be-
tween the groups. We compared the entire SGA group (SGA-S and 
SGA-Cu taken together) to the entire appropriate for gestational 
age (AGA) group (ISS and controls taken together) and we com-
pared all short patients (SGA-S and ISS taken together) to all nor-
mal height individuals (SGA-Cu and controls taken together). We 
also compared the individual patient groups (SGA-Cu vs. SGA-S 
vs. ISS vs. controls).
 For the SNPs that had a significantly different frequency be-
tween the groups, we investigated whether they were associated 
with any of the clinical parameters (birth weight, birth length, birth 
STAT
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 Fig. 1. Interrelationships between GH,  IGFI and insulin signalling [adapted from  42 ].  
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head circumference, and height and weight before the start of GH 
treatment, as well as SBP and DBP) by ANOVA.
 Since we tested associations with clinical parameters for mul-
tiple SNPs, we applied Bonferroni’s correction for the p values ob-
tained by ANOVA by dividing 0.05 by 225 (the number of SNPs 
tested). Only associations with p < 0.0002 (0.05/225) could be con-
sidered significant at an experiment-wide level. For Pearson’s χ 2 
analysis, Bonferroni’s correction was not necessary since multiple 
testing is not an issue there.
 Literature Search 
 For the SNPs which were significantly associated with clinical 
parameters, we searched the literature by entering the refSNP (rs) 
number into PubMed. Furthermore, we searched GWAS Central 
(www.gwascentral.org) for GWAS data about  GH1, GHR, IGF1, 
IGF1R, STAT5A, STAT5B, MAPK1, MAPK3, PPARγ  and INS. 
 Results 
 The study population consisted of 1,437 children: 345 
SGA-S, 288 SGA-Cu, 410 ISS and 394 controls. Pheno-
typic data of the patients are shown in  table 1 . Genotype 
frequencies of all 225 SNPs are shown in online suppl. 
 table 1, see www.karger.com/doi/10.1159/000355409. All 
SNPs were in Hardy-Weinberg equilibrium. We discuss 
the SNPs for which genotype frequencies differed between 
the groups with p values <0.05 and (only for those SNPs) 
we show associations with clinical parameters with p < 
0.05 in  table 2 (table showing all associations found with 
p < 0.05 is available on request). We discuss the results ac-
cording to the clinical parameters studied and according 
to their clinical relevance.
 SNPs Associated with Body Size at Birth (IGF1R SNPs 
rs4966035, rs4966038, rs11247361, rs2715439 and 
rs11247380, IGF1 SNP rs12423791, and PPARγ SNP 
rs2920500) 
 IGF1R SNP rs4966035’s minor allele was more preva-
lent among SGA (12.4 vs. 8.4% in AGA, p = 0.026) and 
was associated with smaller birth length (p = 0.000378, 
entire cohort;  fig. 2 a) and birth weight (p = 0.008, entire 
cohort;  fig. 2 b). The difference in body size at birth was 
not caused by a difference in gestational age: mean gesta-
tional age was 38.7 weeks for all three genotypes ( fig. 2 c). 
 IGF1R SNP rs4966038 is in high linkage disequilibrium 
with rs4966035 (r = 0.85). Therefore, like rs4966035’s mi-
nor allele, the minor allele of rs4966038 CC was more 
prevalent among SGA and associated with smaller birth 
length. The association with birth length remained sig-
nificant after Bonferroni’s correction, but the association 
with birth weight did not.
 IGF1R SNP rs11247361’s minor allele GG was signif-
icantly more frequent in those with normal birth weight: 
16.4% in AGA versus 10.9% in SGA (p = 0.006). It was 
associated with greater birth length (p = 0.004) and birth 
weight in the entire cohort (p = 0.0036) and with lower 
SBP SDS (p = 0.025) in the SGA-Cu cohort. Likewise, 
 IGF1R SNP rs2715439’s A allele was more frequent 
among those born AGA (56.5 vs. 53.3%, p = 0.010) and 
associated with greater birth length and higher DBP (p = 
0.024, all SGA). For the  IGF1R  SNP rs11247380, homo-
zygosity for the A allele was slightly more frequent 
among SGA (32.4 vs. 31.4%, p = 0.048) and it was clear-
ly associated with smaller birth length (p = 0.001, entire 
cohort).
 In  IGF1 , SNP rs12423791’s C allele was more frequent 
among those born AGA (2.1 vs. 1.0%, p = 0.027) and was 
associated with greater birth length and lower DBP SDS. 
No one was homozygous for this minor allele.
 In  PPARγ, SNP rs2920500’s minor allele GG was more 
prevalent in AGA than in SGA (28.9 vs. 22.3%, p = 0.021) 
and was associated with greater birth weight (entire co-
hort, p = 0.017) and greater birth length SDS (entire co-
hort, p = 0.029) as well as greater height (p = 0.01 in the 
entire cohort and 0.001 in controls). Furthermore, the 
heterozygous state was associated with higher SBP SDS 
(SGA-Cu, p = 0.017) and higher DBP SDS (SGA-Cu, p = 
0.008)
 SNPs Associated with Body Size Later in Life 
(IGF1R SNPs rs939626 and rs4965438, MAPK1 SNP 
rs5999842) 
 IGF1R SNP rs939626’s minor allele CC was more 
prevalent among those who were short later in life (SGA-
S and ISS together 24.8 vs. 17.9% in SGA-Cu and controls 
taken together, p = 0.002) and was associated with higher 
weight SDS and BMI SDS in SGA-Cu (p = 0.007 and 
0.041, respectively). It was also associated with DBP SDS 
in SGA (p = 0.031) and ISS (p = 0.039). Likewise,  IGF1R 
SNP rs4965438’s minor allele GG was more prevalent in 
homozygosity among short individuals (6.8 vs. 4.3% in 
individuals of normal adult height, p = 0.024) and was as-
sociated with higher SBP SDS in SGA-S (p = 0.044) and 
all SGA (p = 0.03).
 In MAPK1, SNP rs5999842’s major allele GG was 
more prevalent among those who were short later in life 
(SGA-S and ISS together 72.9 vs. 69.1% in SGA-Cu and 
controls taken together, p = 0.044) and was associated 
with lower height SDS (entire cohort, p = 0.025).
 There was 1 SNP which was associated with body size, 
although its genotype frequency did not differ between 
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the groups:  GH1 SNP rs11079515. For this SNP, GG gen-
otype was associated with lower birth length (entire co-
hort, p = 0.007) and lower SBP SDS (SGA-S, p = 0.008). 
However, this association lost statistical significance after 
Bonferroni’s correction.
 SNPs Associated with Head Circumference (PPARγ 
SNP rs13070963) 
 PPARγ SNP rs13070963’s minor allele CC was more 
prevalent in SGA (p = 0.023) and associated with smaller 
birth head circumference in controls (p = 0.000178).
Table 1.  Phenotypic data of the patients participating in the study
n Mean SD Min Max
Birth length SDS controls 282 –0.23 0.95 –1.87 3.84
SGA-Cu 233 –2.47 1.11 –8.22 0.35
ISS 360 –0.57 0.83 –1.88 3.88
SGA-S 320 –2.74 1.12 –7.42 0.35
Birth weight SDS controls 394 –0.29 1.02 –1.88 4.42
SGA-Cu 286 –2.28 0.88 –4.81 3.34
ISS 409 –0.46 0.86 –1.85 6.75
SGA-S 345 –2.12 0.97 –4.74 0.51
Birth head circumference SDS controls 83 –0.20 1.24 –3.03 3.59
SGA-Cu 123 –1.18 1.24 –3.91 4.09
ISS 225 –0.17 1.06 –3.90 3.33
SGA-S 160 –1.35 1.15 –4.20 2.40
Gestational age, weeks Controls 394 39.3 2.0 30 43
SGA-Cu 286 37.8 3.0 30 43
ISS 410 39.0 2.2 30 42
SGA-S 345 38.4 2.7 30 43
Age at follow-up, years controls 394 24.2 13.6 2.03 59.7
SGA-Cu 286 15.3 9.36 1.95 59.8
ISS 410 29.8 6.23 1.91 40.6
SGA-S 345 8.23 5.83 1.98 27.7
BMI SDS controls 391 0.10 1.10 –3.94 3.68
SGA-Cu 282 –0.08 1.22 –3.25 4.54
ISS 395 –0.35 1.05 –4.86 2.92
SGA-S 339 –0.45 1.08 –4.92 3.58
Height SDS1 controls 394 –0.02 1.07 –1.88 3.27
SGA-Cu 286 –0.55 0.92 –1.88 4.54
ISS 410 –2.48 0.53 –4.86 1.88
SGA-S 345 –2.78 0.69 –5.18 –1.88
Response to GH, ΔhtSDS/year ISS 105 0.03 0.44 –1.73 1.23
SGA-S 214 0.16 0.64 –1.79 6.36
DBP SDS controls 101 0.43 0.95 –2.09 2.50
SGA-Cu 122 0.64 0.91 –1.93 3.65
ISS 316 0.59 0.95 –2.01 4.80
SGA-S 275 0.80 0.94 –2.01 3.60
SBP SDS controls 101 0.62 0.78 –1.55 2.29
SGA-Cu 122 0.63 0.87 –1.97 4.08
ISS 316 0.58 0.72 –1.45 3.07
SGA-S 275 0.66 0.88 –2.66 3.37
ΔhtSDS = Increase in height SDS.
1 Before start of GH treatment (in cases where GH treatment had already started).
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Table 2.  Clinical associations of SNPs in GH1, GHR, IGF1, IGF1R, MAPK1, PPARγ and INS with p < 0.01 or p < 0.05 and genotype fre-
quencies significantly differing between the groups at p < 0.05
Gene SNP Parameter Genotype n Mean SD Min Max p Cohort
GH1 rs11079515 birth length SDS CC 419 –1.44 1.50 –7.42 3.19 0.007 entire cohort
CG 577 –1.36 1.45 –8.22 3.88
GG 183 –1.76 1.55 –6.98 1.49
SBP SDS CC 105 0.61 0.82 –1.54 2.58 0.008 SGA-S
CG 115 0.82 0.83 –0.76 3.37
GG 52 0.38 1.01 –2.66 2.39
GHR rs6898743 GH response, CC 14 0.87 0.85 0.16 3.49 0.01 all SGA
ΔhtSDS/year CG 84 0.75 0.45 –0.46 2.03
GG 114 0.98 0.51 –0.13 2.89
GH response, CC 22 0.71 0.73 –0.25 3.49 0.006 all short
ΔhtSDS/year CG 123 0.70 0.46 –0.46 2.03
GG 166 0.89 0.51 –0.13 2.89
rs719756 SBP SDS AA 61 0.70 0.91 –1.54 2.82 0.035 SGA-S
AT 142 0.73 0.83 –2.12 3.37
TT 66 0.40 0.90 –2.66 2.58
DBP SDS AA 61 0.74 0.91 –1.22 2.99 0.042 SGA-S
AT 142 0.91 0.90 –1.09 3.60
TT 66 0.57 1.02 –2.01 30.07
IGF1 rs12423791 birth length SDS CG 33 –0.88 1.27 –2.74 3.19 0.025 entire cohort
GG 1,143 –1.46 1.49 –8.22 3.88
DBP SDS CG 9 0.13 0.90 –1.41 1.24 0.038 all SGA
GG 381 0.77 0.92 –1.93 3.65
IGF1R rs12901358 SBP SDS CC 56 0.70 0.94 –1.44 4.08 0.025 all SGA
CT 184 0.76 0.87 –2.12 3.37
TT 152 0.50 0.85 –2.66 2.39
SBP SDS CC 40 0.67 0.91 –1.44 2.82 0.039 SGA-S
CT 140 0.77 0.87 –2.12 3.37
TT 91 0.47 0.87 –2.66 2.39
rs11247361 birth length SDS CC 487 –1.48 1.52 –8.22 3.88 0.005 entire cohort
CG 531 –1.50 1.53 –7.19 3.84
GG 153 –1.07 1.24 –3.95 2.67
birth weight SDS CC 576 –1.14 1.32 –4.81 6.75 0.036 entire cohort
CG 631 –1.26 1.32 –4.74 4.42
GG 195 –1.00 1.22 –4.36 3.23
SBP SDS CC 52 0.66 0.99 –1.81 4.08 0.025 SGA-Cu
CG 64 0.69 0.75 –1.97 2.12
GG 3 –0.71 0.36 –1.03 –0.32
rs49660351 birth length SDS AA 123 –1.88 1.46 –6.98 1.22 0.000378 entire cohort
AG 508 –1.30 1.48 –7.42 3.84
GG 556 –1.47 1.48 –8.22 3.88
birth weight SDS AA 144 –1.49 1.24 –4.59 1.48 0.008 entire cohort
AG 606 –1.11 1.30 –4.74 6.75
GG 671 –1.17 1.30 –4.81 3.74
rs11247380 birth length SDS AA 123 –1.86 1.47 –6.98 1.22 0.001 entire cohort
AG 515 –1.30 1.47 –7.42 3.84
GG 550 –1.48 1.48 –8.22 3.88
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Table 2. (continued)
Gene SNP Parameter Genotype n Mean SD Min Max p Cohort
rs4966038 birth length SDS CC 122 –1.74 1.49 –6.98 1.22 0.044 entire cohort
CG 499 –1.37 1.50 –7.42 3.84
GG 552 –1.42 1.46 –8.22 3.88
rs4965438 SBP SDS GG 24 1.01 0.70 –0.68 2.08 0.033 all SGA
GT 130 0.53 0.96 –2.12 4.08
TT 239 0.68 0.83 –2.66 3.37
SBP SDS AA 171 0.66 0.88 –2.66 3.37 0.041 SGA-S
AG 81 0.54 0.86 –2.12 2.37
GG 16 1.14 0.65 –0.21 2.08
rs2715439 birth length SDS AA 328 –1.27 1.50 –7.18 3.88 0.033 entire cohort
AG 619 –1.51 1.48 –8.22 3.19
GG 230 –1.53 1.37 –5.56 1.89
DBP SDS AA 102 0.86 0.93 –1.04 3.65 0.024 all SGA
AG 209 0.79 0.93 –2.01 3.60
GG 78 0.50 0.94 –1.53 2.87
MAPK1 rs5755694 GH response, CC 94 0.67 0.48 –0.46 2.89 0.007 all short
ΔhtSDS/year CT 159 0.84 0.54 –0.35 3.49
TT 64 0.90 0.48 0.08 2.41
GH response, CC 61 0.74 0.52 –0.46 2.89 0.048 all SGA
ΔhtSDS/year CT 109 0.92 0.55 –0.16 3.49
TT 46 0.95 0.45 0.19 2.08
SBP SDS CC 242 0.58 0.81 –2.12 3.07 0.035 entire cohort
CT 400 0.59 0.77 –2.66 2.37
TT 162 0.77 0.85 –1.77 4.08
SBP SDS CC 96 0.47 0.73 –0.93 3.07 0.022 ISS
CT 152 0.57 0.69 –1.45 2.12
TT 63 0.79 0.76 –1.05 2.49
rs5999842 height SDS AA 33 –1.27 1.23 –3.38 1.47 0.025 entire cohort
AG 376 –1.35 1.48 –4.86 3.96
GG 1,007 –1.57 1.45 –5.18 4.54
BMI SDS AA 5 –0.29 0.69 –1.08 0.57 0.039 ISS
AG 108 –0.13 0.98 –2.30 2.79
GG 279 –0.43 1.07 –4.86 2.92
SBP SDS AA 5 1.03 0.58 0.20 1.71 0.036 SGA-Cu
AG 36 0.33 0.91 –1.97 2.04
GG 80 0.75 0.85 –1.77 4.08
PPARγ rs2920500 birth length SDS AA 334 –1.61 1.53 –6.71 3.88 0.010 entire cohort
AG 540 –1.44 1.49 –8.22 3.84
GG 302 –1.26 1.40 –5.44 2.03
birth weight SDS AA 392 –1.34 1.27 –4.72 3.21 0.017 entire cohort
AG 652 –1.15 1.29 –4.81 4.42
GG 366 –1.08 1.32 –4.74 6.75
height SDS AA 392 –1.68 1.42 –5.18 4.54 0.010 entire cohort
AG 653 –1.42 1.44 –5.18 2.66
GG 366 –1.44 1.50 –4.86 3.96
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 SNPs Associated with Response to GH Treatment 
(GHR SNP rs6898743 and MAPK1 SNP rs5755694) 
 We found 2 SNPs associated with increase in height SDS 
during GH treatment with empirical p values below 0.01. 
 GHR SNP rs6898743’s GG genotype was equally prevalent 
among all groups, but it was associated with better re-
sponse to GH (all short, p = 0.006 and all SGA, p = 0.01).
 MAPK1 SNP rs5755694’s CC genotype was equally 
prevalent among all groups, but it was associated with poor-
er response to GH (entire cohort, p = 0.015, all SGA, p = 
0.048 and all short, p = 0.007). However, these associations 
lost statistical significance after Bonferroni’s correction.
 SNPs Associated with Blood Pressure (GHR SNP 
rs719756, IGF1R SNPs rs12901358 and rs11635251) 
 The SNPs which were more frequent among those 
who were short later in life were all associated with high-
er blood pressure. 
 For  GHR  SNP rs719756, the A allele was more frequent 
among those who remain short (50 vs. 45% in individuals 
with normal adult height, p = 0.009) and was associated 
with higher SBP SDS (SGA-S, p = 0.035) and higher DBP 
SDS (SGA-S, p = 0.042).
 For  IGF1R SNP rs12901358, the C allele was more fre-
quent among those who remain short (41 vs. 37%, p = 
0.009) and was associated with higher SBP SDS (all SGA, 
p = 0.025 and SGA-S, p = 0.039).  IGF1R SNP rs11635251’s 
minor allele GG was more prevalent among short (6.4 vs. 
3.9% in non-short, p = 0.035) and was associated with 
higher SBP SDS in the entire cohort (p = 0.021), with 
higher DBP SDS and SBP SDS in all SGA (p = 0.011 and 
0.006, respectively) and with SBP SDS in SGA-S (p = 
0.041).
 For  STAT5A, STAT5B, MAPK3  and INS , we did not 
find any significant associations with body size, response 
to GH treatment or blood pressure.
Table 2. (continued)
Gene SNP Parameter Genotype n Mean SD Min Max p Cohort
DBP SDS AA 34 0.47 0.89 –1.93 1.93 0.008 SGA-Cu
AG 54 0.93 0.87 –0.66 3.65
GG 33 0.39 0.85 –1.34 2.11
SBP SDS AA 34 0.61 0.77 –1.81 2.12 0.017 SGA-Cu
AG 54 0.87 0.87 –0.77 4.08
GG 33 0.35 0.80 –1.77 1.71
rs13070963 birth head CC 3 –2.14 0.85 –2.95 –1.25 0.000178 controls
circumference SDS CT 37 0.30 1.25 –1.65 3.59
TT 43 –0.50 1.02 –3.03 2.16
 All SGA = SGA-Cu and SGA-S; all short = SGA-S and ISS; ΔhtSDS = increase in height SDS.
1 Association remained significant after Bonferroni’s correction.
Birth length SDS
A/A A/A A/G G/GA/G G/G
p = 0.000378, entire cohort
a Birth weight SDS
p = 0.008, entire cohort
b Gestational age
A/GA/A G/G
p = 0.98, entire cohort
c
 Fig. 2. Birth length SDS ( a ), birth weight SDS ( b ) and gestational age at birth ( c ) according to  IGF1R SNP rs4966035 genotype. 
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 Discussion 
 We investigated 225 SNPs in 10 genes reported to be 
involved in pre- and/or postnatal growth and glucose me-
tabolism:  GH1, GHR, IGF1, IGF1R, STAT5A, STAT5B, 
MAPK1, MAPK3, PPARγ  and INS . We found several 
clinical associations for  GH1, GHR, IGF1, IGF1R, PPARγ 
 and MAPK1 . For  STAT5A, STAT5B, MAPK3  and INS , we 
did not find any significant associations with body size, 
response to GH treatment, SBP or DBP.
 We mainly focused on SNPs for which the genotype 
frequency significantly differed between the groups 
(SGA-Cu vs. SGA-S vs. ISS vs. controls, short vs. normal 
height, SGA vs. non-SGA). However, we also found 3 
SNPs which also raised our interest (although they did 
not meet this criterion):  GH1 SNP rs1109515,  GHR SNP 
rs6898743 and  MAPK1 SNP rs5755694. Although their 
associations did not remain significant after Bonferroni’s 
correction, we chose to show these associations since the 
purpose of this study is exploratory. In this case, applying 
Bonferroni’s correction too strictly can cause false-nega-
tive results  [24] . For all associations found, we suggest 
they be further investigated and replicated in other co-
horts.
 One SNP showed statistically significant genotype dif-
ferences between the patient groups and showed associa-
tions with clinical parameters which remained significant 
after Bonferroni’s correction:  IGF1R SNP rs 4966035. The 
minor (A–) allele of this SNP was more prevalent among 
SGA (12.4 vs. 8.4% in AGA, p = 0.026). rs4966035’s minor 
allele A was associated with smaller birth length: birth 
length SDS was –1.88 in AA versus –1.30 and –1.47 SDS 
in AG and GG, respectively (p = 0.000378, entire cohort). 
rs4966035’s minor allele A was also associated with birth 
weight (p = 0.008, entire cohort). An interesting literature 
finding was that Haataja et al.  [25] related rs4966038 (in 
high linkage disequilibrium with rs4966035) to spontane-
ous preterm birth susceptibility. However, the association 
with body size at birth which we found was not caused by 
a difference in gestational age: mean gestational age was 
38.7 weeks for all 3 rs4966035 genotypes. rs4966035 was 
also related to insulin secretion index by Naj et al.  [26] . 
Montasser et al.  [27] found that rs4966035 was associated 
with DBP using generalized estimation equation regres-
sion methods in non-smokers but not in smokers. How-
ever, using bayesian quantitative trait nucleotide method 
which they also used, this association was non-significant.
 For all SNPs associated with size at birth, we searched 
the literature for previously found associations. IGF1R 
SNP rs11247361 was also studied by Haataja et al.  [25] in 
relation to spontaneous preterm birth. They did not find 
any association. For  IGF1R SNP rs11247380, we did not 
find any publications in relation to clinical parameters. 
 IGF1R SNP rs2715439 was described in relation to insulin 
levels and insulin sensitivity index  [26] , but not to size at 
birth or blood pressure. 
 In the literature,  IGF1 SNP rs12423791 was reported 
in relation to myopia  [28, 29] , but not to growth or blood 
pressure. 
 PPARγ SNP rs2920500’s minor allele GG was less 
prevalent in SGA than in AGA and was associated with 
greater birth weight, birth length and height SDS. Fur-
thermore, the heterozygous state was associated with 
higher SBP SDS and higher DBP SDS. The finding that 
genetic polymorphisms in the heterozygous state can be 
associated with a certain phenotype, which can differ 
from the two homozygous states, has been previously re-
ported and has been the subject of research and discus-
sion  [30–39] . This might be a reflection of trans-regula-
tion, i.e. the interaction of two alleles in trans, which 
might explain advantages or disadvantages of heterozy-
gosity as found in several studies and for rs2920500 in our 
study. However, it might also reflect pure coincidence. 
We did not find any articles about rs2920500 in the lit-
erature.
 IGF1R SNP rs939626’s minor allele CC was more 
prevalent among short individuals and was associated 
with higher weight SDS and with BMI SDS in SGA-Cu. It 
was also associated with DBP SDS in SGA and ISS. How-
ever, the direction of the association was opposite in SGA 
vs. ISS, which renders it less likely that this is a ‘real’ as-
sociation. We did not find any publications about this 
SNP in relation to clinical parameters. 
 We did not find any publications about  IGF1R SNP 
rs4965438 and  MAPK1 SNP rs5999842 in relation to clin-
ical parameters.
 We checked whether the relevant SNPs from impor-
tant GWAS, like the large height GWAS of Lango Allen 
et al.  [40] , were also significant in our cohort. rs2871865 
showed an association with height (height SDS decreased 
according to genotype from CC –1.46 to CG –1.58 and 
GG –1.84 SDS), but this was not significant (p = 0.20). 
This discrepancy is probably due to size and phenotype 
differences between the populations studied.
 PPARγ SNP rs13070963’s minor allele CC was more 
prevalent in SGA and associated with smaller birth head 
circumference in controls. However, since the minor al-
lele was present in only 3 patients, it is hard to draw any 
conclusions from this. We did not find any articles about 
this SNP in the literature.
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